Deupirfenidone Compared to Placebo and Pirfenidone in Idiopathic Pulmonary Fibrosis: ELEVATE IPF Phase 2b Trial

作者
Toby M. Maher,Miguel Angel Bergna,Amy Hajari Case,Won-Il Choi,Mark J. Hamblin,Tejaswini Kulkarni,Jessica E. Shore,Ioannis P. Tomos,Αrgyris Τzouvelekis,David A. Golod,Eric Elenko,YANQIONG ZHANG,Camilla S. Graham,Jin Woo Song,E I Astashkin On Behalf Of The Linkor Study Investigators
出处
期刊:American Journal of Respiratory and Critical Care Medicine [American Thoracic Society]
卷期号:211 (Supplement_1): A7046-A7046 被引量:3
标识
DOI:10.1164/ajrccm.2025.211.abstracts.a7046
摘要

Abstract Rationale: Deupirfenidone (DPF) is a deuterated form of pirfenidone with a differentiated pharmacokinetic profile that enables higher plasma exposure, potentially allowing for improved efficacy and tolerability in individuals with idiopathic pulmonary fibrosis (IPF). Methods: Phase 2b, international, multi-center, randomized, double-blind, active- and placebo-comparator trial investigated the safety, tolerability, and efficacy of DPF 550 mg TID and DPF 825 mg TID compared to placebo and pirfenidone 801 mg TID (PFD). The primary endpoint was the rate of change in forced vital capacity (FVC) over 26 weeks and the key secondary endpoint was the rate of change in FVC percent predicted (FVCpp) over 26 weeks. Additional endpoints included time to disease progression and safety. The primary statistical analyses compared absolute FVC (mL) and FVCpp between the combined arms of DPF and the placebo arm using a Bayesian approach. Secondary statistical analyses used a frequentist approach. Both utilized a mixed model for repeated measures (MMRM), treating time as a continuous variable. Results: 257 patients were enrolled from 14 countries; median age: 72.0; 71.2% male; median baseline FVC (n= 254): 2580.0 mL; and FVCpp: 77.5%. Double-blinded study treatment completion was 80.0%, 68.3%, 64.6%, and 78.1% for placebo, PFD, DPF 550 mg, and DPF 825 mg arms, respectively. Using Bayesian analysis, the posterior probability that the pooled DPF arms had less decline compared to placebo in FVC (mL) was 98.5% and in FVCpp was 99.6%. Using a frequentist analysis, the change from baseline in FVC (mL) and FVCpp over 26 weeks is shown in the Figure. Treatment-emergent adverse events commonly associated with antifibrotics (%) were nausea (7.7, 27.0, 16.9, 20.3), dyspepsia (3.1, 22.2, 12.3, 14.1), diarrhea (9.2, 11.1, 10.8, 7.8), abdominal pain (4.6, 7.9, 6.2, 14.1), photosensitivity reaction (0, 7.9, 6.2, 7.8), decreased appetite (7.7, 14.3, 18.5, 20.3), fatigue (1.5, 11.1, 7.7, 9.4), dizziness (3.1, 7.9, 9.2, 12.5), and headache (4.6, 12.7, 7.7, 3.1) for placebo, PFD, DPF 550 mg, and DPF 825 mg arms, respectively. Conclusions: Deupirfenidone met both FVC and FVCpp endpoints in the primary Bayesian approach and a dose response between 550 mg and 825 mg was demonstrated. DPF 825 mg also met both endpoints, demonstrated statistical significance by a frequentist approach, and had an FVC decline that approached the level seen with the normal aging process. Deupirfenidone was well tolerated at both doses and safety was consistent with previous studies. These data support continued development of deupirfenidone in patients with IPF.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
新月完成签到,获得积分10
1秒前
nemo完成签到,获得积分10
1秒前
1秒前
1秒前
Zhang发布了新的文献求助10
2秒前
lucas发布了新的文献求助10
2秒前
2秒前
3秒前
3秒前
3秒前
4秒前
薛薛薛发布了新的文献求助10
4秒前
深情安青的应助被葡萄采纳,获得10
4秒前
huang完成签到,获得积分10
4秒前
Owen的应助被JJJ采纳,获得10
5秒前
SZn发布了新的文献求助10
5秒前
6秒前
wdz洲发布了新的文献求助10
6秒前
魔幻的舞蹈完成签到,获得积分10
6秒前
7秒前
7秒前
10秒前
scimaker发布了新的文献求助10
10秒前
10秒前
10秒前
qianqian发布了新的文献求助10
10秒前
Mix完成签到,获得积分10
10秒前
11秒前
xingx完成签到 ,获得积分10
12秒前
脑洞疼的应助被Dobrzs采纳,获得10
13秒前
ding的应助被tt采纳,获得10
13秒前
安详的觅风完成签到,获得积分10
13秒前
pluto的应助被8R采纳,获得10
14秒前
邱邱科研发布了新的文献求助10
14秒前
Pursue。发布了新的文献求助10
14秒前
15秒前
chope发布了新的文献求助10
15秒前
大吱吱完成签到,获得积分10
16秒前
lucas完成签到,获得积分10
16秒前
文静紫霜完成签到 ,获得积分10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189472
求助须知:如何正确求助?哪些是违规求助? 9576774
关于积分的说明 21849709
捐赠科研通 7787422
什么是DOI,文献DOI怎么找? 3435600
关于科研通互助平台的介绍 2559782
邀请新用户注册赠送积分活动 2482552